Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04881097
Other study ID # NNF 20OC0064760
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date August 1, 2025

Study information

Verified date November 2022
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study will provide information on cognitive impairment and Health related quality of life in patients surviving 12 months after acute brain injury, generate a hypothesis of useful variables to predict cognitive impairment or low levels of HRQoL, and potentially inform interventions for the prevention and treatment of cognitive impairment following neuro-ICU stay.


Description:

The aim is to 1) measure the frequency and extent of cognitive impairment after acute brain injury at six and 12-months after neuro-Intensive care unit (ICU) admission 2) explore the association between cognitive impairment at six and 12 months after ICU admission with the following potential risk factors: duration of ICU delirium (days), duration of sepsis (days), duration of post traumatic amnesia (days) and the severity of brain injury (initial Glasgow Coma Scale , 3) describe Health related quality of life, functional disability and frailty at six and 12 after ICU admission and 4) explore the association between the functional disability, frailty and health-related quality of life at 12 months after ICU admission


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 1, 2025
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 110 Years
Eligibility Inclusion Criteria: - Traumatic brain injury - Spontaneous intracranial hemorrhage - Ischemic stroke - An anticipated stay in the neuro-ICU for 48 hours or longer. Exclusion Criteria: - Persistent coma defined as Richmond Agitation-Sedation Scale (RASS) -5 to -3 throughout the neuro-ICU stay - Congenital brain injury - Suspected pre-existing Cognitive impairment (Informant Questionnaire on cognitive decline in the elderly (IQCODE): 3.3 or more) (regardless of cause) - Permanent residence outside Denmark - Inability to communicate in Danish

Study Design


Intervention

Behavioral:
no intervention
no intervention

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Aalborg University Hospital, Aarhus University Hospital, Odense University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Global cognitive function measured by The Repeatable Battery for the Assessment of Neuropsychological Status, Overall score (mean 100; SD=15). Higher scores indicate better cognitive functioning. from baseline to 6 months after ICU admission
Primary Change in Global cognitive function measured by The Repeatable Battery for the Assessment of Neuropsychological Status, Overall score (mean 100; SD=15). Higher scores indicate better cognitive functioning. from baseline to 12 months after ICU admission
Primary Change in Executive function measured by Trail Making Test B, Score indicate time in seconds to complete task, the higher speed (less seconds) indicates higher executive function from baseline to 6 months after ICU admission
Primary Change in Executive function measured by Trail Making Test B, Score indicate time in seconds to complete task, the higher speed (less seconds) indicates higher executive function from baseline to 12 months after ICU admission
Secondary Change in Health related quality of life after brain injury measured with a disease specific questionnaire:Quality of Life after Brain Injury overall scale (QOLIBRI-OS). Scores are from 0-100, the higher the score the more quality of life. from baseline to 6 months after ICU admission
Secondary Change in Health related quality of life after brain injury measured with a disease specific questionnaire:Quality of Life after Brain Injury overall scale (QOLIBRI-OS). Scores are from 0-100, the higher the score the more quality of life. from baseline to 12 months after ICU admission
Secondary Delirium measured by Confusion measured by CAM-ICU or Intensive Care Delirium Screening Checklist (ICDSC). during the procedure (ICU stay) up to 30 days
Secondary Change in Disability after head injury/nontraumatic acute brain insults I measured by Glasgow outcome scale extended (GOSE). Scores from 1 to 8, higher scores indicate less disability from baseline to 6 months after ICU admission
Secondary Change in Disability after head injury/nontraumatic acute brain insults I measured by Glasgow outcome scale extended (GOSE). Scores from 1 to 8, higher scores indicate less disability from baseline to 12 months after ICU admission
Secondary Change in Disability after head injury/nontraumatic acute brain insults II measured by Extended disability rating scale (DRS). Scores from 0 to 29, the higher the score the more disability from baseline to 6 months after ICU admission
Secondary Change in Disability after head injury/nontraumatic acute brain insults II measured by Extended disability rating scale (DRS). Scores from 0 to 29, the higher the score the more disability from baseline to 12 months after ICU admission
Secondary Change in Frailty measured by the Clinical Frailty Scale (CFS). Scale is from 1 to 9 ( the higher score the more frail). baseline to 6 months after ICU admission
Secondary Change in Frailty measured by the Clinical Frailty Scale (CFS). Scale is from 1 to 9 ( the higher score the more frail). baseline to 12 months after ICU admission
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3